

# SAFETY DATA SHEET

**Genentech**  
A Member of the Roche Group

## ACTIVASE Vials 50 mg

Version  
1.0

Revision Date:  
06/13/2025

Date of last issue: -  
Date of first issue: 06/13/2025

### SECTION 1. IDENTIFICATION

Product name : ACTIVASE Vials 50 mg

Product code : RO553-2960/F03-00

Common name(s),  
synonym(s) of the substance : CATHFLO

#### Manufacturer or supplier's details

Company name of supplier : Genentech, Inc.

Address : 1 DNA Way  
South San Francisco, CA 94080  
USA

Telephone : 001-(650) 225-1000

E-mail address : info.sds@roche.com

Emergency telephone

In case of emergencies: : US CHEMTREC PHONE (800)-424-9300

#### Recommended use of the chemical and restrictions on use

Recommended use : Formulated pharmaceutical active substance

---

### SECTION 2. HAZARDS IDENTIFICATION

#### GHS classification in accordance with the OSHA Hazard Communication Standard (29 CFR 1910.1200)

Combustible dust

#### GHS label elements

Signal Word : Warning

Hazard Statements : May form combustible dust concentrations in air.

#### Other hazards

None known.

---

### SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

#### Components

Chemical name	CAS-No.	Concentration (% w/w)
Alteplase	105857-23-6	2.14
Sorbitan, mono-(9Z)-9-octadecenoate, poly(oxy-1,2-ethanediyl) derivs.	9005-65-6	0.21
L-Arginine	74-79-3	

**ACTIVASE Vials 50 mg**Version  
1.0Revision Date:  
06/13/2025Date of last issue: -  
Date of first issue: 06/13/2025

| Phosphoric acid

| 7664-38-2 |

**SECTION 4. FIRST AID MEASURES**

General advice : Do not leave the victim unattended.

If inhaled : If unconscious, place in recovery position and seek medical advice.  
If symptoms persist, call a physician.

In case of skin contact : Wash off with soap and water.

In case of eye contact : Flush eyes with water as a precaution.  
Remove contact lenses.  
Protect unharmed eye.  
Keep eye wide open while rinsing.  
If eye irritation persists, consult a specialist.

If swallowed : Induce vomiting immediately and call a physician.  
Keep respiratory tract clear.  
Do not give milk or alcoholic beverages.  
Never give anything by mouth to an unconscious person.  
If symptoms persist, call a physician.

Most important symptoms and effects, both acute and delayed : None known.

Protection of first-aiders : First Aid responders should pay attention to self-protection and use the recommended protective clothing

Notes to physician : Treat symptomatically.

**SECTION 5. FIRE-FIGHTING MEASURES**

Suitable extinguishing media : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.

Unsuitable extinguishing media : High volume water jet

Specific hazards during fire fighting : No information available.

Hazardous combustion products : Carbon dioxide (CO<sub>2</sub>), carbon monoxide (CO), oxides of nitrogen (NO<sub>x</sub>), dense black smoke.  
Phosphorus compounds  
Carbon monoxide  
Nitrogen oxides (NO<sub>x</sub>)  
Sulfur oxides

**ACTIVASE Vials 50 mg**Version  
1.0Revision Date:  
06/13/2025Date of last issue: -  
Date of first issue: 06/13/2025

Further information : Standard procedure for chemical fires.  
Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.

Special protective equipment for fire-fighters : Wear self-contained breathing apparatus for firefighting if necessary.

---

**SECTION 6. ACCIDENTAL RELEASE MEASURES**

Personal precautions, protective equipment and emergency procedures : Avoid dust formation.  
Avoid breathing dust.  
Refer to protective measures listed in sections 7 and 8.

Environmental precautions : Prevent further leakage or spillage if safe to do so.  
If the product contaminates rivers and lakes or drains inform respective authorities.

Methods and materials for containment and cleaning up : Keep in suitable, closed containers for disposal.

---

**SECTION 7. HANDLING AND STORAGE**

Advice on protection against fire and explosion : Provide appropriate exhaust ventilation at places where dust is formed.

Advice on safe handling : For personal protection see section 8.  
Smoking, eating and drinking should be prohibited in the application area.  
Dispose of rinse water in accordance with local and national regulations.

Conditions for safe storage : Keep container tightly closed in a dry and well-ventilated place.  
Electrical installations / working materials must comply with the technological safety standards.

Storage temperature : 2 °C to 8 °C  
Protect from heat and light  
Protect from moisture.

Further information on storage stability : No decomposition if stored and applied as directed.

Packaging material : Suitable material: glass, Stainless steel, glass bottles

---

**SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION****Ingredients with workplace control parameters**

**ACTIVASE Vials 50 mg**
Version  
1.0Revision Date:  
06/13/2025Date of last issue: -  
Date of first issue: 06/13/2025

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Phosphoric acid	7664-38-2	TWA	1 mg/m <sup>3</sup>	ACGIH
		STEL	3 mg/m <sup>3</sup>	ACGIH
		TWA	1 mg/m <sup>3</sup>	NIOSH REL
		ST	3 mg/m <sup>3</sup>	NIOSH REL
		TWA	1 mg/m <sup>3</sup>	OSHA Z-1
		TWA	1 mg/m <sup>3</sup>	OSHA P0
		STEL	3 mg/m <sup>3</sup>	OSHA P0
Alteplase	105857-23-6	IOEL	0.2 mg/m <sup>3</sup>	Roche Industrial Hygiene Committee (RIHC)

**Personal protective equipment**

**Respiratory protection** : General and local exhaust ventilation is recommended to maintain vapor exposures below recommended limits. Where concentrations are above recommended limits or are unknown, appropriate respiratory protection should be worn. Follow OSHA respirator regulations (29 CFR 1910.134) and use NIOSH/MSHA approved respirators. Protection provided by air purifying respirators against exposure to any hazardous chemical is limited. Use a positive pressure air supplied respirator if there is any potential for uncontrolled release, exposure levels are unknown, or any other circumstance where air purifying respirators may not provide adequate protection.

**Hand protection**

Material : Nitrile rubber  
 Break through time : > 30 min  
 Glove thickness : > 0.11 mm

Material : butyl-rubber  
 Break through time : > 480 min  
 Glove thickness : > 0.4 mm

**Remarks** : Wear appropriate protective gloves to prevent skin contact. Replace torn or punctured gloves promptly.

**Eye protection** : Eye wash bottle with pure water  
 Tightly fitting safety goggles

**Skin and body protection** : Dust impervious protective suit  
 Choose body protection according to the amount and concentration of the dangerous substance at the work place.

**Hygiene measures** : When using do not eat or drink.  
 When using do not smoke.  
 Wash hands before breaks and at the end of workday.

**ACTIVASE Vials 50 mg**Version  
1.0Revision Date:  
06/13/2025Date of last issue: -  
Date of first issue: 06/13/2025**SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES**

Appearance : solid, (lyophilized)

Color : white, off-white

Odor : Not applicable

Odor Threshold : Not applicable

pH : No data available

Melting point/ range : No data available

Boiling point/boiling range : No data available

Flash point : Not applicable

Evaporation rate : No data available

Self-ignition : No data available

Upper explosion limit / Upper flammability limit : No data available

Lower explosion limit / Lower flammability limit : No data available

Vapor pressure : No data available

Relative vapor density : Not applicable

Relative density : No data available

Density : No data available

Solubility(ies)  
Water solubility : No data available

Solubility in other solvents : No data available

Partition coefficient: n-octanol/water : No data available

Autoignition temperature : No data available

Decomposition temperature : No data available

**ACTIVASE Vials 50 mg**

Version 1.0 Revision Date: 06/13/2025 Date of last issue: -  
Date of first issue: 06/13/2025

Viscosity  
Viscosity, dynamic : Not applicable  
Viscosity, kinematic : Not applicable  
Explosive properties : No data available  
Oxidizing properties : No data available  
Metal corrosion rate : Not corrosive to metals.

Particle characteristics  
Particle Size Distribution : No data available

---

**SECTION 10. STABILITY AND REACTIVITY**

Reactivity : No dangerous reaction known under conditions of normal use.  
Chemical stability : Stable under normal conditions.  
Possibility of hazardous reactions : No decomposition if stored and applied as directed.  
Conditions to avoid : No data available  
Incompatible materials : No data available  
Not applicable  
Hazardous decomposition products : No data available  
No hazardous decomposition products are known.

---

**SECTION 11. TOXICOLOGICAL INFORMATION****Acute toxicity**

Not classified due to lack of data.

**Product:**

Acute oral toxicity : Acute toxicity estimate: 2,176 mg/kg  
Method: Calculation method

**Components:****L-Arginine:**

Acute oral toxicity : LD50 Oral (Rat, male and female): > 5,110 mg/kg

**Phosphoric acid:**

**ACTIVASE Vials 50 mg**Version  
1.0Revision Date:  
06/13/2025Date of last issue: -  
Date of first issue: 06/13/2025

Acute oral toxicity : LD50 Oral (Rat): > 300 - < 2,000 mg/kg  
Method: OECD Test Guideline 423

**Alteplase:**

Acute oral toxicity : Remarks: Not bioavailable by oral administration

Acute toxicity (other routes of administration) : TDLo (Rat): > 10 mg/kg  
Application Route: i.v.

**Skin corrosion/irritation**

Based on available data, the classification criteria are not met.

**Product:**

Result : No skin irritation  
Remarks : Expert judgment

**Components:****L-Arginine:**

Species : Rabbit  
Method : OECD Test Guideline 404  
Result : No skin irritation  
GLP : no

**Phosphoric acid:**

Result : Causes burns.  
Remarks : Expert judgment

**Serious eye damage/eye irritation**

Based on available data, the classification criteria are not met.

**Product:**

Result : No eye irritation  
Remarks : Expert judgment

**Components:****L-Arginine:**

Species : Rabbit  
Result : No eye irritation  
Method : OECD Test Guideline 405

**ACTIVASE Vials 50 mg**Version  
1.0Revision Date:  
06/13/2025Date of last issue: -  
Date of first issue: 06/13/2025**Phosphoric acid:**

Result : Risk of serious damage to eyes.  
Remarks : Expert judgment

**Respiratory or skin sensitization****Skin sensitization**

Not classified due to lack of data.

**Respiratory sensitization**

Not classified due to lack of data.

**Product:**

Assessment : No eye irritation, No skin irritation

**Germ cell mutagenicity**

Not classified due to lack of data.

**Components:****L-Arginine:**

Genotoxicity in vitro : Test Type: reverse mutation assay  
Test system: *Salmonella typhimurium*  
Metabolic activation: with and without metabolic activation  
Method: OECD Test Guideline 471  
Result: negative

**Alteplase:**

Genotoxicity in vitro : Test Type: Chromosome aberration test in vitro  
Test system: mammalian cells  
Result: negative

Test Type: Ames test  
Result: negative

**Carcinogenicity**

Not classified due to lack of data.

**IARC** No ingredient of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.

**OSHA** No component of this product present at levels greater than or equal to 0.1% is on OSHA's list of regulated carcinogens.

**NTP** No ingredient of this product present at levels greater than or equal to 0.1% is identified as a known or anticipated carcinogen by NTP.

**Reproductive toxicity**

Not classified due to lack of data.

**ACTIVASE Vials 50 mg**Version  
1.0Revision Date:  
06/13/2025Date of last issue: -  
Date of first issue: 06/13/2025**Components:****Alteplase:**

Effects on fetal development : Test Type: reproductive and developmental toxicity study  
Species: Rabbit  
Application Route: i.v.  
General Toxicity Maternal: NOEL: 1 mg/kg bw/day  
Embryo-fetal toxicity.: NOEL: 1 mg/kg bw/day  
Symptoms: No embryo-fetal toxicity., No maternal effects.

Test Type: reproductive and developmental toxicity study  
Species: Rat  
Application Route: i.v.  
General Toxicity Maternal: NOEL: 1 mg/kg bw/day  
Embryo-fetal toxicity.: NOEL: 1 mg/kg bw/day  
Symptoms: No embryo-fetal toxicity., No maternal effects.

Test Type: reproductive and developmental toxicity study  
Species: Rabbit  
Application Route: i.v.  
General Toxicity Maternal: 3 mg/kg bw/day  
Embryo-fetal toxicity.: 3 mg/kg bw/day  
Symptoms: No maternal effects., Embryolethal effects.,  
Embryotoxic effects.

**STOT-single exposure**

Not classified due to lack of data.

**STOT-repeated exposure**

Not classified due to lack of data.

**Repeated dose toxicity****Product:**

Repeated dose toxicity - : No eye irritation, No skin irritation  
Assessment

**Components:****L-Arginine:**

Species : Rat, male  
NOAEL : 3,130.9 mg/kg  
Exposure time : 13 Weeks

**Alteplase:**

Species : Several species  
LD0 : 10 mg/kg  
Application Route : i.v.  
Exposure time : 14 d

## ACTIVASE Vials 50 mg

Version  
1.0Revision Date:  
06/13/2025Date of last issue: -  
Date of first issue: 06/13/2025**Aspiration toxicity**

Not classified due to lack of data.

**Further information****Product:**

Remarks : No data available

**Components:****Alteplase:**

Remarks : anaphylactic reactions may occur following the intravenous application of proteins; rare cases of hypersensitivity have been described with other monoclonal antibodies

---

**SECTION 12. ECOLOGICAL INFORMATION****Ecotoxicity****Components:****L-Arginine:**

Toxicity to fish : LC50 (Brachydanio rerio (zebrafish)): 2,800 mg/l  
Exposure time: 96 h  
Method: OECD Test Guideline 203  
GLP: yes

**Ecotoxicology Assessment**

Acute aquatic toxicity : This product has no known ecotoxicological effects.

Chronic aquatic toxicity : This product has no known ecotoxicological effects.

Toxicity Data on Soil : Not expected to adsorb on soil.

Other organisms relevant to the environment : No data available

**Phosphoric acid:**

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): > 100 mg/l  
End point: Immobilization  
Exposure time: 48 h  
Test Type: static test  
Analytical monitoring: yes  
Method: OECD Test Guideline 202  
GLP: yes

Toxicity to algae/aquatic plants : EC50 (Desmodesmus subspicatus (green algae)): > 100 mg/l  
End point: Growth rate  
Exposure time: 72 h  
Test Type: static test  
Method: OECD Test Guideline 201

NOEC (Desmodesmus subspicatus (green algae)): 100 mg/l  
End point: Growth rate

**ACTIVASE Vials 50 mg**Version  
1.0Revision Date:  
06/13/2025Date of last issue: -  
Date of first issue: 06/13/2025

Exposure time: 72 h  
Test Type: static test  
Method: OECD Test Guideline 201

**Persistence and degradability****Components:****L-Arginine:**

Biodegradability : Result: Readily biodegradable.

**Phosphoric acid:**

Biodegradability : Remarks: The methods for determining the biological degradability are not applicable to inorganic substances.

**Alteplase:**

Biodegradability : Result: Globular proteins are generally well biodegradable

**Bioaccumulative potential****Components:****L-Arginine:**

Partition coefficient: n-octanol/water : log Pow: -4.2 (68 °F / 20 °C)

**Phosphoric acid:**

Partition coefficient: n-octanol/water : Remarks: No data available

**Alteplase:**

Partition coefficient: n-octanol/water : Remarks: No data available

**Mobility in soil**

No data available

**Other adverse effects****Product:**

Ozone-Depletion Potential : Regulation: 40 CFR Protection of Environment; Part 82 Protection of Stratospheric Ozone - CAA Section 602 Class I Substances  
Remarks: This product neither contains, nor was manufactured with a Class I or Class II ODS as defined by the U.S. Clean Air Act Section 602 (40 CFR 82, Subpt. A, App.A + B).

Additional ecological information : No data available

**ACTIVASE Vials 50 mg**Version  
1.0Revision Date:  
06/13/2025Date of last issue: -  
Date of first issue: 06/13/2025**Components:****L-Arginine:**

Adsorbed organic bound halogens (AOX) : Remarks: Not applicable

Additional ecological information : No data available

**Alteplase:**

Additional ecological information : Protein with highly specific affinity to a certain antigen; therefore, no appreciable ecotoxic potential is to be expected

---

**SECTION 13. DISPOSAL CONSIDERATIONS****Disposal methods**

Waste from residues : Do not dispose of waste into sewer.  
Do not contaminate ponds, waterways or ditches with chemical or used container.  
Send to a licensed waste management company.

Contaminated packaging : Empty remaining contents.  
Dispose of as unused product.  
Do not re-use empty containers.

---

**SECTION 14. TRANSPORT INFORMATION****International Regulations****UNRTDG**

Not regulated as a dangerous good

**IATA-DGR**

Not regulated as a dangerous good

**IMDG-Code**

Not regulated as a dangerous good

**Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code**

Not applicable

**Domestic regulation****49 CFR**

Not regulated as a dangerous good

**Special precautions for user**

Remarks : Not dangerous goods in the meaning of ADR/RID, ADN, IMDG-Code, ICAO/IATA-DGR

---

**SECTION 15. REGULATORY INFORMATION****CERCLA Reportable Quantity**

Listed substances in the product are at low enough levels to not be expected to exceed the RQ

**ACTIVASE Vials 50 mg**
Version  
1.0Revision Date:  
06/13/2025Date of last issue: -  
Date of first issue: 06/13/2025
**SARA 304 Extremely Hazardous Substances Reportable Quantity**

This material does not contain any components with a section 304 EHS RQ.

**SARA 302 Extremely Hazardous Substances Threshold Planning Quantity**

Components	CAS-No.	Component TPQ (lbs)
<b>SARA 311/312 Hazards</b>	:	Combustible dust

**Clean Air Act**

This product neither contains, nor was manufactured with a Class I or Class II ODS as defined by the U.S. Clean Air Act Section 602 (40 CFR 82, Subpt. A, App.A + B).

This product does not contain any hazardous air pollutants (HAP), as defined by the U.S. Clean Air Act Section 112 (40 CFR 61).

This product does not contain any chemicals listed under the U.S. Clean Air Act Section 112(r) for Accidental Release Prevention (40 CFR 68.130, Subpart F).

This product does not contain any chemicals listed under the U.S. Clean Air Act Section 111 SOCMI Intermediate or Final VOC's (40 CFR 60.489).

**Clean Water Act**

The following Hazardous Substances are listed under the U.S. CleanWater Act, Section 311, Table 116.4A:

Phosphoric acid 7664-38-2 >= 20 - < 30 %

The following Hazardous Chemicals are listed under the U.S. CleanWater Act, Section 311, Table 117.3:

Phosphoric acid 7664-38-2 >= 20 - < 30 %

This product does not contain any toxic pollutants listed under the U.S. Clean Water Act Section 307

This product does not contain any priority pollutants related to the U.S. Clean Water Act

**US State Regulations**
**Massachusetts Right To Know**

Phosphoric acid 7664-38-2

**Pennsylvania Right To Know**

L-Arginine 74-79-3  
Phosphoric acid 7664-38-2

**Maine Chemicals of High Concern**
**Vermont Chemicals of High Concern**
**Washington Chemicals of High Concern**
**California List of Hazardous Substances**

Phosphoric acid 7664-38-2

**California Permissible Exposure Limits for Chemical Contaminants**

Phosphoric acid 7664-38-2

**The ingredients of this product are reported in the following inventories:**

AIIC : Not in compliance with the inventory

DSL : This product contains the following components that are not on the Canadian DSL nor NDSL.

Alteplase

## ACTIVASE Vials 50 mg

Version  
1.0

Revision Date:  
06/13/2025

Date of last issue: -  
Date of first issue: 06/13/2025

NZIoC	:	On the inventory, or in compliance with the inventory
ENCS	:	Not in compliance with the inventory
ISHL	:	Not in compliance with the inventory
KECI	:	Not in compliance with the inventory
PICCS	:	Not in compliance with the inventory
IECSC	:	Not in compliance with the inventory
TCSI	:	Not in compliance with the inventory
TSCA	:	Product contains substance(s) not listed on TSCA inventory.
TECI	:	Not in compliance with the inventory

### TSCA list


No substances are subject to a Significant New Use Rule.

No substances are subject to TSCA 12(b) export notification requirements.

## SECTION 16. OTHER INFORMATION

### Further information

#### NFPA 704:



#### HMIS® IV:



HMIS® ratings are based on a 0-4 rating scale, with 0 representing minimal hazards or risks, and 4 representing significant hazards or risks. The "\*" represents a chronic hazard, while the "/" represents the absence of a chronic hazard.

### Full text of other abbreviations

ACGIH	:	USA. ACGIH Threshold Limit Values (TLV)
NIOSH REL	:	USA. NIOSH Recommended Exposure Limits
OSHA P0	:	USA. Table Z-1-A Limits for Air Contaminants (1989 vacated)

## ACTIVASE Vials 50 mg

Version  
1.0Revision Date:  
06/13/2025Date of last issue: -  
Date of first issue: 06/13/2025

OSHA Z-1	values)
ACGIH / TWA	: USA. Occupational Exposure Limits (OSHA) - Table Z-1 Limits for Air Contaminants
ACGIH / STEL	: 8-hour, time-weighted average
NIOSH REL / TWA	: Short-term exposure limit
NIOSH REL / ST	: Time-weighted average concentration for up to a 10-hour workday during a 40-hour workweek
OSHA P0 / TWA	: STEL - 15-minute TWA exposure that should not be exceeded at any time during a workday
OSHA P0 / STEL	: 8-hour time weighted average
OSHA Z-1 / TWA	: Short-term exposure limit
	: 8-hour time weighted average

AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CERCLA - Comprehensive Environmental Response, Compensation, and Liability Act; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DOT - Department of Transportation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; EHS - Extremely Hazardous Substance; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; HMIS - Hazardous Materials Identification System; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; MSHA - Mine Safety and Health Administration; n.o.s. - Not Otherwise Specified; NFPA - National Fire Protection Association; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NTP - National Toxicology Program; NZIoc - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; RCRA - Resource Conservation and Recovery Act; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RQ - Reportable Quantity; SADT - Self-Accelerating Decomposition Temperature; SARA - Superfund Amendments and Reauthorization Act; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Revision Date : 06/13/2025

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information given is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and is not to be considered a warranty or quality specification. The information relates only to the

# SAFETY DATA SHEET

**Genentech**  
A Member of the Roche Group

## ACTIVASE Vials 50 mg

Version  
1.0

Revision Date:  
06/13/2025

Date of last issue: -  
Date of first issue: 06/13/2025

specific material designated and may not be valid for such material used in combination with any other materials or in any process, unless specified in the text.

US / EN / 2404